Sarepta's shares also dropped about 15% when the biopharma said last month it was planning to ask the FDA to approve its fourth Duchenne muscular dystrophy treatment as soon as next year. Now, Sarepta is attempting to add to its gene editing pipeline through the collaboration with GenEdit. The biotech was cofounded by CEO Kunwoo Lee, Ph.D., who worked on CRISPR-Cas9-based research in DMD with CRISPR pioneer Jennifer Doudna while he was at the University of California, Berkeley. RELATED: Sarepta, with pivotal data in sight, dumps Lysogene gene therapy GenEdit's nonviral polymer nanoparticles are meant to stave off safety concerns while delivering gene editing therapeutics to specific tissues with functional activity maintained after repeat dosing.